New medicine for active psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had psoriatic arthritis for at least 6 months and currently have at least 3 swollen and 3 tender joints.
- You have plaque psoriasis (a skin condition with red, scaly patches) or a history of it.
- You have a blood test showing a certain level of inflammation (hs-CRP 3 mg/L or higher).
- You have either never taken a biologic medicine for psoriatic arthritis, or you have tried only one TNF-inhibitor (like adalimumab/Humira) and it didn't work well or caused problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This study tests an oral medicine called zasocitinib for people with psoriatic arthritis who have not had enough relief from other treatments. It may help reduce joint pain and skin symptoms.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.